Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor ...

I t’s hard to overstate just how revolutionary the development of medications like Ozempic and Wegovy has been for managing ...

Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that the first set of ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed orally, and is Novo Nordisk's third drug in the class after daily injectable Victoza (liraglutide) and weekly shot Ozempic ...

The reserarchers found that a weekly dose of semaglutide was effective at treating Metabolic Dysfunction-Associated ...